X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
guc5 (14) 14
humans (13) 13
index medicus (13) 13
male (13) 13
oncology (13) 13
original reports (12) 12
middle aged (10) 10
aged (9) 9
prostatic neoplasms - drug therapy (8) 8
adult (7) 7
antineoplastic combined chemotherapy protocols - therapeutic use (7) 7
aged, 80 and over (6) 6
orchiectomy (6) 6
treatment outcome (6) 6
prostate-specific antigen - blood (5) 5
prostatic neoplasms - surgery (5) 5
docetaxel (4) 4
female (4) 4
guc6 (4) 4
mitoxantrone (4) 4
taxoids - administration & dosage (4) 4
taxoids - therapeutic use (4) 4
antineoplastic combined chemotherapy protocols - adverse effects (3) 3
carcinoma (3) 3
combination (3) 3
disease-free survival (3) 3
end-points (3) 3
guc4 (3) 3
kaplan-meier estimate (3) 3
neoplasm invasiveness (3) 3
phase-ii (3) 3
prednisone (3) 3
prostatic neoplasms - blood (3) 3
prostatic neoplasms - mortality (3) 3
prostatic neoplasms - pathology (3) 3
taxoids - adverse effects (3) 3
time factors (3) 3
trial (3) 3
urinary bladder neoplasms - pathology (3) 3
adenocarcinoma - drug therapy (2) 2
adenocarcinoma - secondary (2) 2
analgesics, non-narcotic - administration & dosage (2) 2
analgesics, non-narcotic - adverse effects (2) 2
androgen antagonists - therapeutic use (2) 2
androstenes (2) 2
animals (2) 2
antineoplastic agents - adverse effects (2) 2
antineoplastic agents - therapeutic use (2) 2
bios3 (2) 2
carcinoma, transitional cell - drug therapy (2) 2
carcinoma, transitional cell - mortality (2) 2
circulating tumor-cells (2) 2
cisplatin - administration & dosage (2) 2
clinical-trials (2) 2
cystectomy (2) 2
disease progression (2) 2
doxorubicin - administration & dosage (2) 2
estramustine (2) 2
expression (2) 2
guc2 (2) 2
guc3 (2) 2
men (2) 2
neoplasm metastasis (2) 2
neoplasm staging (2) 2
organometallic compounds - administration & dosage (2) 2
organometallic compounds - adverse effects (2) 2
organophosphorus compounds - administration & dosage (2) 2
organophosphorus compounds - adverse effects (2) 2
prednisone - administration & dosage (2) 2
proportional hazards models (2) 2
prostate-specific antigen - analysis (2) 2
psc14 (2) 2
survival (2) 2
testosterone (2) 2
to23 (2) 2
united states (2) 2
urinary bladder neoplasms - drug therapy (2) 2
urinary bladder neoplasms - mortality (2) 2
vinblastine - administration & dosage (2) 2
working group (2) 2
adenocarcinoma - immunology (1) 1
adenocarcinoma - surgery (1) 1
administration, oral (1) 1
adrenal androgens (1) 1
advanced thyroid-cancer (1) 1
analgesics, non-narcotic - therapeutic use (1) 1
androgens (1) 1
androstenols - administration & dosage (1) 1
androstenols - adverse effects (1) 1
androstenols - therapeutic use (1) 1
angiogenesis (1) 1
angiogenesis inhibitors - administration & dosage (1) 1
antibiotics, antineoplastic - administration & dosage (1) 1
antibodies, monoclonal - administration & dosage (1) 1
antibodies, monoclonal, humanized (1) 1
antigen (1) 1
antineoplastic agents - administration & dosage (1) 1
antineoplastic agents - pharmacokinetics (1) 1
antineoplastic agents, alkylating - administration & dosage (1) 1
antineoplastic agents, phytogenic - administration & dosage (1) 1
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


by International Collaboration of Trialists on behalf of the Medical Research Council Advanced Bladder Cancer Working Party (now the National Cancer Research Institute Bladder Cancer Clinical Studies Group), the European Organisation for Research and Treatment of Cancer Genito-Urinary Tract Cancer Group, the Australian Bladder Cancer Study Group, the National Cancer Institute of Canada Clinical Trials Group, Finnbladder, Norwegian Bladder Cancer Study Group, and Club Urologico Espanol de Tratamiento Oncologico Group and Norwegian Bladder Canc Study Grp and Med Res Council Adv Bladder Canc and Club Urologico Espanol Tratamiento and Australian Bladder Cancer Study Group and European Organisation for Research and Treatment of Cancer Genito-Urinary Tract Cancer Group and Finnbladder and International Collaboration of Trialists and National Cancer Institute of Canada Clinical Trials Group and Medical Research Council Advanced Bladder Cancer Working Party (now the National Cancer Research Institute Bladder Cancer Clinical Studies Group) and Norwegian Bladder Cancer Study Group and Club Urologico Espanol de Tratamiento Oncologico Group and International Collaboration of Trialists on behalf of the Medical Research Council Advanced Bladder Cancer Working Party (now the National Cancer Research Institute Bladder Cancer Clinical Studies Group), the European Organisation for Research and Treatment of Cancer Genito-Urinary Tract Cancer Group, the Australian Bladder Cancer Study Group, the National Cancer Institute of Canada Clinical Trials Group, Finnbladder, Norwegian Bladder Cancer Study Group, and Club Urologico Espanol de Tratamiento Oncologic
Journal of Clinical Oncology, ISSN 0732-183X, 06/2011, Volume 29, Issue 16, pp. 2171 - 2177
Journal Article
Journal Article
Journal Article
Journal of Clinical Oncology, ISSN 0732-183X, 04/2010, Volume 28, Issue 12, pp. 2070 - 2076
Journal Article
Journal Article
Journal of Clinical Oncology, ISSN 0732-183X, 05/2009, Volume 27, Issue 15, pp. 2436 - 2442
Journal Article
Journal of Clinical Oncology, ISSN 0732-183X, 02/2009, Volume 27, Issue 5, pp. 812 - 826
Nearly 40 years ago, President Richard Nixon signed the National Cancer Act, mobilizing the country's resources to make the "conquest of cancer a national... 
TRIAL | STAGE BREAST-CANCER | WOMEN | MELANOMA | ONCOLOGY | ADVANCED THYROID-CANCER | PROSTATE-CANCER | LETROZOLE | PHASE-II | FINASTERIDE | SORAFENIB | United States | Humans | Central Nervous System Neoplasms - therapy | Male | Lung Neoplasms - therapy | Gastrointestinal Neoplasms - therapy | Research | Sarcoma - therapy | Breast Neoplasms - therapy | Urogenital Neoplasms - therapy | Genital Neoplasms, Female - therapy | Medical Oncology - trends | Financing, Government - trends | Female | Child | Bone2 | Bone1 | To19 | To18 | To17 | Asco Special | To16 | Dxst | To25 | To24 | To23 | To22 | To21 | To20 | Sarc8 | Sarc7 | Dxst3 | Hsr1 | Sarc6 | Hsr2 | Sarc5 | Dxst1 | Sarc4 | Dxst2 | Thor3 | Thor4 | Thor5 | Thor6 | Psc14 | Psc13 | Thor7 | Thor8 | Thor9 | Neur6 | Neur4 | Neur5 | Neur3 | Gic20 | Pedi2 | Pedi3 | Gic2 | Gic19 | Gic18 | Gic4 | Gic3 | Thor11 | Gic6 | Gic5 | Gic11 | Gic9 | Gic10 | Gic13 | Gic12 | Guc3 | Guc4 | Gic17 | Gic16 | Guc2 | Gync10 | Gync11 | Gic31 | Gic30 | Gync16 | Gync17 | Gync18 | Gync19 | Gync12 | Sarc14 | Gync13 | Sarc15 | Sarc12 | Sarc13 | Pedi10 | Gic24 | Gic23 | Gic26 | Gic25 | Gic27 | Hema7 | Gync20 | Hema8 | Hema5 | Hema6 | Gic40 | Gdln1 | Hema19 | Hema15 | Hema14 | Hema13 | Hema12 | Hema11 | Gic33 | To15 | Gic32 | To14 | Gic34 | Gic37 | Gic39 | Gic38 | Guc5 | Guc6 | Guc18 | Guc17 | Guc16 | Guc9 | Guc13 | Guc12 | Guc11 | Gync2 | Guc10 | Gync4 | Hema24 | Gync3 | Hema23 | Gync6 | Hema22 | Gync5 | Hema21 | Hema20 | Bc4 | Bc3 | Gync9 | Bc6 | Hnc3 | Hnc12 | Bc5 | Hnc4 | Hnc13 | Hnc10 | Hnc2 | Hnc11 | Hnc5 | Hnc6 | Hnc9
Journal Article
Journal of Clinical Oncology, ISSN 0732-183X, 07/2009, Volume 27, Issue 20, pp. 3319 - 3324
Purpose Samarium-153 (Sm-153) lexidronam is a bone-targeting radiopharmaceutical with a short physical half-life and a favorable toxicity profile. We evaluated... 
BONE-TARGETED THERAPY | TRIAL | PREDNISONE | MITOXANTRONE | ONCOLOGY | MEN | SKELETAL METASTASES | ENDOTHELIN-1 | CARCINOMA | ESTRAMUSTINE | Neutrophils - cytology | Prostatic Neoplasms - radiotherapy | Humans | Middle Aged | Fatigue - etiology | Male | Antineoplastic Agents - therapeutic use | Feasibility Studies | Dose-Response Relationship, Drug | Taxoids - therapeutic use | Neoplasm Metastasis | Antineoplastic Agents - adverse effects | Analgesics, Non-Narcotic - adverse effects | Aged, 80 and over | Organometallic Compounds - therapeutic use | Pain - etiology | Prostatic Neoplasms - blood | Leukocyte Count | Prostatic Neoplasms - drug therapy | Taxoids - adverse effects | Organophosphorus Compounds - adverse effects | Radioisotopes - therapeutic use | Drug Administration Schedule | Organometallic Compounds - adverse effects | Radioisotopes - adverse effects | Organophosphorus Compounds - therapeutic use | Analgesics, Non-Narcotic - administration & dosage | Combined Modality Therapy | Analgesics, Non-Narcotic - therapeutic use | Constipation - etiology | Prostate-Specific Antigen - blood | Orchiectomy | Taxoids - administration & dosage | Platelet Count | Aged | Organophosphorus Compounds - administration & dosage | Cohort Studies | Organometallic Compounds - administration & dosage | Index Medicus | ORIGINAL REPORTS | Guc5
Journal Article
Journal of Clinical Oncology, ISSN 0732-183X, 09/2009, Volume 27, Issue 25, pp. 4062 - 4067
Journal Article
No results were found for your search.

Cannot display more than 1000 results, please narrow the terms of your search.